Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Antibodies from AxioMx

Premium

AxioMx this week launched its new custom recombinant antibody discovery and development services, which include epitope mapping and antigen design as well as antibody screening, optimization, and production.

The company's proprietary phage display libraries and "rapid liquid" screening and affinity maturation methods enable it to produce monoclonal antibodies in as little as eight weeks, it said.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.